Skip to main content
OpenTrials
Completed

NCT Number: NCT06431074

Radicle Calm 24: A Study of Health and Wellness Products on Feelings of Anxiety and Related Health Outcomes

A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on feelings of anxiety and related health outcomes

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anxiety Anxiety Disorders Mental Disorders Stress

Age range

21 year–105 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Radicle Science, Inc

Del Mar, California, 92014, United States

About this study

This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States.

Eligible participants will (1) endorse a desire for less feelings of anxiety (2) have the opportunity for meaningful improvement (at least 30%) in their primary health outcome, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.

Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded.

Self-reported data are collected electronically from eligible participants over 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults, at least 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities. Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed
  • Resides in the United States
  • Endorses less anxiety as a primary desire
  • Has the opportunity for at least 20% improvement in their primary health outcome
  • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study

Exclusion criteria

  • Reports being pregnant, trying to become pregnant, or breastfeeding
  • Unable to provide a valid US shipping address and mobile phone number
  • Reports current enrollment in another clinical trial
  • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
  • Unable to read and understand English
  • Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
  • Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients. NYHA (New York Heart Association) Class Ill or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
  • Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients. Anticoagulants, antihypertensive, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOls (monoamine oxidase inhibitors), or thyroid products
  • Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s)
  • Lack of reliable daily access to the internet

Treatment and study plan

Placebo Control Form 1

Dietary Supplement

Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.

Calm Active Study Product 1.1 Usage

Dietary Supplement

Participants will use their Radicle Calm Active Study Product 1.1 as directed for a period of 6 weeks.

Placebo Control 6.1

Dietary Supplement

Participants will use their Placebo Control 6.1 as directed for a period of 6 weeks.

Calm Active Study Product 6.1 Usage

Dietary Supplement

Participants will use their Radicle Calm Active Study Product 6.1 as directed for a period of 6 weeks.

Primary outcomes

  1. Change in feelings of anxiety

    Time frame: 6 weeks

    Mean difference in feelings of anxiety score as assessed by Patient Reported Outcome Measurement System (PROMIS) Anxiety 8A (scale 8-40; where lower scores correspond to less feelings of anxiety)

Secondary outcomes

  1. Change in stress

    Time frame: 6 weeks

    Mean difference in stress score as assessed by Perceived Stress Scale 4 (PSS-4) (scale 0-16; where lower scores correspond to less stress)

  2. Change in sleep

    Time frame: 6 weeks

    Mean difference in sleep score as assessed by Patient Reported Outcome Measurement System (PROMIS) Sleep Disturbance 4A (scale 4-20; where lower scores correspond to better sleep quality/less sleep disturbance)

  3. Change in mood (emotional distress)

    Time frame: 6 weeks

    Mean difference in mood score as assessed by Patient Reported Outcome Measurement System (PROMIS) Emotional Distress-Depression 4A (scale 4-20; where lower scores correspond to lower levels of emotional distress)

  4. Minimal clinically important difference (MCID) in feelings of anxiety

    Time frame: 6 weeks

    Likelihood of achieving a MCID in sleep disturbance, as measured by Patient Reported Outcome Measurement System (PROMIS) Anxiety 8A (scale 8-40; where lower scores correspond to less feelings of anxiety)

  5. Minimal clinically important difference (MCID) in stress

    Time frame: 6 weeks

    Likelihood of experiencing minimal clinically important difference in stress score as assessed by Perceived Stress Scale 4 (PSS-4) (scale 0-16; where lower scores correspond to less stress)

  6. Minimal clinically important difference (MCID) in sleep

    Time frame: 6 weeks

    Likelihood of experiencing minimal clinically important difference in sleep score as assessed by Patient Reported Outcome Measurement System (PROMIS) Sleep Disturbance 4A (scale 4-20; where lower scores correspond to better sleep quality/less sleep disturbance)

  7. Minimal clinically important difference (MCID) in mood (emotional distress)

    Time frame: 6 weeks

    Likelihood of experiencing minimal clinically important difference in mood score as assessed by Patient Reported Outcome Measurement System (PROMIS) Emotional Distress-Depression 4A (scale 4-20; where lower scores correspond to lower levels of emotional distress)

Other outcomes

  1. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (1)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based IgG (Immunoglobulin) biomarker. (Optional; among consented participants only).

  2. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (2)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based cytokines (Interleukin 1 beta, Interleukin 8, Tumor necrosis factor-alpha, and Interleukin 6) biomarker. (Optional; among consented participants only).

  3. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (3)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based dehydroepiandrosterone sulfate (DHEA-S) biomarker. (Optional; among consented participants only).

  4. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (4)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based estradiol biomarker. (Optional; among consented participants only).

  5. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (5)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based progesterone biomarker. (Optional; among consented participants only).

  6. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (6)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based testosterone biomarker. (Optional; among consented participants only).

  7. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (7)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based cortisol biomarker. (Optional; among consented participants only).

  8. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (8)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based melatonin biomarker. (Optional; among consented participants only).

  9. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (9)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based C-Reactive Protein (CRP) biomarker. (Optional; among consented participants only).

  10. Change in blood concentration of at-home (direct-to-consumer) specimen assay (1)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based cortisol biomarker (1 drop). (Optional; among consented participants only).

  11. Change in blood concentration of at-home (direct-to-consumer) specimen assay (2)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based homocysteine biomarker (1 drop). (Optional; among consented participants only).

  12. Change in blood concentration of at-home (direct-to-consumer) specimen assay (3)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based ferritin biomarker (1 drop). (Optional; among consented participants only).

  13. Change in blood concentration of at-home (direct-to-consumer) specimen assay (4)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based thyroid stimulating hormone (TSH) biomarker (1 drop). (Optional; among consented participants only).

  14. Change in blood concentration of at-home (direct-to-consumer) specimen assay (5)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based hemoglobin A1C (HbA1c) biomarker (1 drop). (Optional; among consented participants only).

  15. Change in blood concentration of at-home (direct-to-consumer) specimen assay (6)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based insulin biomarker (1 drop). (Optional; among consented participants only).

  16. Change in blood concentration of at-home (direct-to-consumer) specimen assay (7)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based vitamin D biomarker (1 drop). (Optional; among consented participants only).

  17. Change in blood concentration of at-home (direct-to-consumer) specimen assay (8)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based dehydroepiandrosterone sulfate (DHEA-S) biomarker (1 drop). (Optional; among consented male participants only).

  18. Change in blood concentration of at-home (direct-to-consumer) specimen assay (9)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based testosterone biomarker (1 drop) (Optional; among consented male participants only).

  19. Change in blood concentration of at-home (direct-to-consumer) specimen assay (10)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based estradiol biomarker (1 drop). (Optional; among consented participants only).

  20. Change in blood concentration of at-home (direct-to-consumer) specimen assay (11)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based follicle-stimulating hormone (FSH) biomarker (1 drop). (Optional; among consented female participants only).

  21. Change in blood concentration of at-home (direct-to-consumer) specimen assay (12)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based total cholesterol (high-density lipoproteins (HDL) and low-density lipoproteins (LDL)) biomarker (1 drop). (Optional; among consented participants only).

  22. Change in blood concentration of at-home (direct-to-consumer) specimen assay (13)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based triglycerides (apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB)) (1 drop). (Optional; among consented participants only).

  23. Change in stool concentration of at-home (direct-to-consumer) specimen assay

    Time frame: 6 weeks

    Mean difference in stool concentration as assessed by a stool sample (microbial diversity) (Optional; among consented participants only).

Sponsors and collaborators

Lead sponsor

Radicle Science

Industry

Registry information

Official study title

Radicle Calm™ 24: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Feelings of Anxiety and Related Health Outcomes

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
May 28, 2024
Registry last updated
Aug 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.